Get started
Author

Francesca Alletto

Lipophagy Impairment Is Associated With Disease Progression in NAFLD
2020 · Simone Carotti, Katia Aquilano, et al. · Frontiers in Physiology · 120
PDF
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase
2020 · Simone Carotti, Katia Aquilano, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 56
Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown
2022 · Felice Cinque, Annalisa Cespiati, et al. · Nutrients · 15
PDF
Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register
2023 · Elena Succurro, Alessio Novella, et al. · Internal and Emergency Medicine · 5
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study
2024 · Carlotta Franchi, Raffaella Rossio, et al. · Internal and Emergency Medicine · 3
PDF
Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades
2023 · Rosa Lombardi, Lucia Colavolpe, et al. · Digestive and Liver Disease · 2
PDF
Comparison of metabolic alterations, hepatic and cardiovascular damage between primary NAFLD and HIV-associated NAFLD: Role of low visceral adiposity
2023 · R. Lombardi, F. Cinque, et al. · Digestive and Liver Disease · 2
Liver Fibrosis and IRS1 rs2972146 Are Associated With Weight Loss Response After Metabolic Bariatric Surgery
2026 · Felice Cinque, Marica Meroni, et al. · Diabetes Obesity and Metabolism
PDF
Liver Fibrosis and IRS1 rs2972146 Are Associated With Insufficient Weight Loss After Bariatric Metabolic Surgery
2026 · Elena Corbetta, Felice Cinque, et al. · Digestive and Liver Disease
PDF
Author response for "Liver Fibrosis and IRS1 rs2972146 Are Associated With Weight Loss Response After Metabolic Bariatric Surgery"
2026 · Felice Cinque, Marica Meroni, et al.
Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry
2026 · Paolo Lido, Sara Ratti, et al. · Internal and Emergency Medicine
Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register
2026 · Marta Chiara Sircana, Alfredo Caturano, et al. · Internal and Emergency Medicine
PDF
Lysosomal Acid Lipase Activity as a Novel Biomarker of Histological Progression in Masld: a Single-center Prospective Study
2026 · Rosa Lombardi, Carola Garavaglia, et al. · Atherosclerosis
Prescribing cascades among hospitalized older adults: a retrospective cohort study from the REPOSI registry
2026 · Alice Restelli, Chiara Crippa, et al. · Internal and Emergency Medicine
THU-158 Are current MASLD alcohol thresholds appropriate for all patients? The role of metabolic vulnerability
2026 · Rosa Lombardi, Felice Cinque, et al. · Journal of Hepatology
THU-091-YI Epicardial adipose tissue as a marker of divergent hepatic and cardiovascular trajectories in MASLD: a prospective study
2026 · Francesca Alletto, Annalisa Cespiati, et al. · Journal of Hepatology
WED-137 Real-life evaluation of the FIB-4 two-step fibrosis screening strategy in MASLD: measurement of waist circumference might make the difference
2026 · Rosa Lombardi, Andrea Dalbeni, et al. · Journal of Hepatology
Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease
2026 · Rosa Lombardi, Felice Cinque, et al. · Hepatology International
PDF
Unnecessary use of proton pump inhibitors in patients discharged on oral anticoagulant therapy: data from the REPOSI registry
2025 · Chiara Elli, Alessio Novella, et al. · Internal and Emergency Medicine
Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic masld patients: a genetic perspective
2025 · F. Alletto, A. Cespiati, et al. · Digestive and Liver Disease
Correction to: Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register
2023 · Elena Succurro, Alessio Novella, et al. · Internal and Emergency Medicine
PDF
Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications
2023 · Rosa Lombardi, Jaqueline Currà, et al. · Journal of Hepatology
Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD
2022 · Francesca Alletto, Paolo Francione, et al. · Journal of Hepatology
Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity
2022 · Felice Cinque, Rosa Lombardi, et al. · Journal of Hepatology
Prevalence of sarcopenia and cardiovascular alterations in a cohort of non-cirrhotic MAFLD patients
2022 · A. Cespiati, R. Lombardi, et al. · Digestive and Liver Disease
Works count: 27
Citation count: 203
H-index: 4
I10-index: 3
Year
Topic
Type